Savolitinib

Drug Profile

Savolitinib

Alternative Names: AZD-6094; HMP-504; HMPL-504; Volitinib

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazines; Triazoles
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Adenocarcinoma; Lung cancer; Non-small cell lung cancer
  • Phase I Gastric cancer; Solid tumours

Most Recent Events

  • 29 Sep 2017 Efficacy and adverse events data from a phase I trial in Gastric cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) released by Hutchison Pharma
  • 06 Sep 2017 AstraZeneca initiates enrolment in a phase I trial in Healthy volunteers in USA (PO) (NCT03258515)
  • 29 Aug 2017 AstraZeneca plans a phase I trial in Healthy volunteers in USA (NCT03258515)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top